Introducing the Alliance for Pulmonary Hypertension’s New Board of Directors 2026-2029 We are proud to introduce the new Board of the Alliance for Pulmonary Hypertension — a group of dedicated patient advocates bringing decades of combined experience to our mission of improving life for people living with pulmonary hypertension across the world. Pisana Ferrari, President […]
How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026
This “How I Do It” article addresses a practical question now facing pulmonary arterial hypertension (PAH) clinicians: as sotatercept gets added to background combination treatment, some patients on prostacyclin therapy show sustained improvement — raising the question of whether their prostacyclin dose can be safely reduced. The challenge is that standard monitoring tools (functional class,
Suzanne Lea, Career pivot post transplant: finding new passion after pulmonary hypertension full transcript
Career Pivot Post-Transplant: Finding New Passion After Pulmonary Hypertension I’m going to talk to you today about career pivots after being diagnosed with pulmonary hypertension or, in my case, even more so after transplant. Let’s go back a bit. As well as inheriting pulmonary hypertension through my DNA — I had a genetic form —
When science and AI converge- the evolving landscape of Pulmonary Arterial Hypertension (PAH) care – webinar, slides, and transcript (part 2)
DOWNLOAD THE SLIDES *Remote monitoring technologies and solutions – Paula Appenzeller MD *Online mental health resources and peer support – Dr Gregg H. Rawlings *HeartWorks: The New Pulmonary Hypertension Mobile Research & Resources App for Patients, Caregivers & HCPs – Steve Van Wormer FULL TRANSCRIPT – COMING SOON SHORT SUMMARY In this AfPH webinar, speakers
Do financial conflicts of interest influence medical prescribing practices? A Yale study published in Medical XPress, June 16, 2026
A Yale study, published in Pulmonary Circulation, examined links between pharmaceutical industry payments and prescribing patterns among physicians treating pulmonary arterial hypertension (PAH) — a field chosen because therapies are costly and prescribing is concentrated among a small group of specialists. Using CMS Open Payments data, researchers found that physicians receiving drug-specific industry payments were
Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition
Bronchiolitis obliterans syndrome (BOS) is the most common form of chronic lung allograft dysfunction after lung transplant, marked by progressive small airway disease with limited treatment options. This case report describes a 55-year-old woman with primary ciliary dyskinesia, post-bilateral lung transplant, who developed severe (stage 3) bronchiolitis obliterans syndrome and went into respiratory failure requiring
Ayotunde Omitogun, founder of the Cardiac Community in Nigeria, receives prestigious 2026 Rino Aldrighetti Leadership Award by the Pulmonary Hypertension Association (PHA) – June 18, 2026
The Rino Aldrighetti Leadership Award is the highest honor presented by the Pulmonary Hypertension Association (PHA). The award honors people who have shown outstanding leadership, commitment, and worldwide influence in raising PH awareness, supporting patients, and pushing forward treatment options. Omitogun was diagnosed with pulmonary hypertension in 2013 after a congenital heart defect, and over
Inhaled Therapies for Pulmonary Hypertension: Where We Are and What’s Next, Live PHA webinar on July 23, 2026 at 2 pm EDT
Pulmonary hypertension treatments continue to evolve and one very promising advancing treatment option is inhaled therapy which delivers medication directly to the lungs. The webinar speakers will discuss the current landscape and future of inhaled therapies in pulmonary hypertension, including:• Currently approved inhaled therapies.• Key differences between inhaled treatment options and the conditions they manage,
Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026
Earlier this month, Liquidia Corporation presented four posters at the US Pulmonary Hypertension Association (PHA)’s International Conference in Dallas, sharing 24‑week ASCENT study data and broader insights on YUTREPIA (treprostinil) inhalation powder in pulmonary hypertension. Beyond clinical outcomes, the company highlighted patient‑reported cough data, the mental health strain on caregivers and the evolving role of
A roundtable of US pulmonologists discusses sotatercept, de-escalation, and the limits of upfront therapy for pulmonary arterial hypertension, HCP Live, June 22, 2026
An HCPLive roundtable of pulmonologists from UCLA, Cedars-Sinai, and community practices discussed optimizing pulmonary arterial hypertension management. Key points: Treatment sequencing: Upfront dual oral combination therapy (ERA + PDE5 inhibitor) remains standard for non-high-risk patients, though sotatercept hasn’t formally displaced it despite growing clinical interest. An Italian study cited at the roundtable found about a
Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension, European Respiratory Journal, May 2026
GLP-1 receptor agonists (GLP-1RAs) are drugs originally developed for diabetes and obesity. In experimental models of pulmonary arterial hypertension GLP-1RA’s administration attenuates the severity of pulmonary hypertension. Additional studies highlight their ability to protect against lung fibrosis and preserve endothelial function. No clinical trials have yet tested GLP-1RAs specifically in pulmonary arterial hypertension, though observational
Corsair Pharma Announces Three Presentations of Phase 1 Clinical Data for TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association Conference
Corsair Pharma‘s experimental skin patch designed to deliver treprostinil, an approved treatment for pulmonary arterial hypertension (PAH), appears to be working as intended, according to newly announced data from an early clinical trial in healthy volunteers. Several treprostinil formulations are already approved for pulmonary arterial hypertension: subcutaneous 24/7 infusion (Remodulin and generics), oral (Orenitram, not
Regeneron Pharmaceuticals expands Into pulmonary arterial hypertension with Phase 2 trial for REGN13335
Regeneron Pharmaceuticals, a U.S. biotech, is running a Phase 2 trial of REGN13335, an Anti-PDGF-B monoclonal antibody, in adults with pulmonary arterial hypertension who are already on standard treatment. It’s a randomized, placebo-controlled, quadruple-blind study (patients, doctors, investigators, and assessors are all kept in the dark during the main phase) to gauge what extra benefit
Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension, Frontiers in Cardiovascular Medicine, May 21, 2026
This single-center retrospective study, conducted at Qilu Hospital, Shandong University (China), from February 2022 to November 2023, set out to compare two strategies for selexipag-based triple combination therapy in patients with pulmonary arterial hypertension (PAH): starting all three drugs together (initial/upfront triple therapy) versus adding selexipag on top of existing dual therapy (early sequential triple
The Japanese Circulation Society, in response to advocacy by PHA Japan, publishes lay summary of the pulmonary hypertension guidelines, June 8, 2026
The Japanese Circulation Society, in response to advocacy from the Japanese pulmonary hypertension patient association PHA Japan, has published a patient-friendly lay summary of the pulmonary hypertension guidelines. The document aims to help patients and families better understand their condition and treatment options, and to facilitate more equal, informed conversations with their doctors. As the
Congratulations to Louise Bouman, Member of the Board of the Alliance for Pulmonary Hypertension, for her election as Chair of the United Patient Advisory Group of the European Lung Foundation (ELF)!
At the Alliance for Pulmonary Hypertension we are very proud that Louise Bouman, Member of our Board, has been elected as Chair of the UPAG (United Patient Advisory Group) of the European Lung Foundation, United Patient Advisory Group within the European Lung Foundation (ELF), a collaborative network consisting of representatives from various condition-specific Patient Advisory
Haemodynamic Responses to Sotatercept and Parenteral Prostacyclins in Pulmonary Arterial Hypertension Patients, Journal of Heart and Lung Transplantation, June 1, 2026
French researchers retrospectively evaluated the haemodynamic trajectory of 62 patients with pulmonary arterial hypertension (PAH) who sequentially received parenteral prostacyclins and sotatercept as part of the French early access program. They found that both treatments lowered the resistance in the blood vessels of the lungs, making it easier for blood to flow. However, the treatments worked
AI imaging company Qureight brings together leading pulmonary hypertension experts on new Scientific Advisory Board, Biospace, May 5, 2026
Qureight is an end-to-end imaging Clinical Research Organization (CRO) that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease. It is developing its deep learning AI imaging models to support ongoing clinical trials in the pulmonary hypertension field, where there is demand for robust non-invasive ways to
New study aims to see how triple combination therapy with sotatercept affects pulmonary vascular resistance in patient with newly diagnosed pulmonary arterial hypertension
New study aims to see how 24 weeks of triple therapy with an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and sotatercept, affects pulmonary vascular resistance (PVR) in patients with newly diagnosed pulmonary arterial hypertension. SIRIUS is a 24-week, single-arm, open-label study with up to 42 days of screening and a 28-day safety follow-up.
Cereno Scientific announces partnership with PHA Europe on patient-centered pulmonary hypertension drug design, May 11, 2026
Swedish biotech Cereno Scientific has announced a collaboration with PHA Europe & Global, aimed at integrating the patient perspective more systematically into clinical trial design and execution. Cereno is developing two experimental medications that could expand choices in this space: CS1 for pulmonary arterial hypertension (PAH) and CS014 for pulmonary hypertension associated with lung disease (PH-ILD). The